Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China.

IGFBP-3 positively and negatively impacts on IGF1-induced lung cancer development.

IGF-I correlates with systemic inflammation and seems to play an independent predictive role in metastatic non-small cell lung cancer.

Heavy smokers carrying susceptible IGF1, IGF2, and IGFBP3 polymorphisms have a higher risk of lung cancer.

miR-486 directly targets components of insulin growth factor (IGF) signaling including IGF1, IGF1 receptor, and phosphoinositide-3-kinase, regulatory subunit 1alpha (PIK3R1, or p85a) and functions as a potent tumor suppressor of lung cancer.

TM4SF4 expression was correlated with the increased expression of IGF1, consequently resulting in IGF1R activation in lung adenocarcinoma.

progression of lung cancer in mice treated with IGF-1 was significantly increased as compared to the group treated with IGF-1+AG1024 or the control group, with the same trend mirrored in IGF-1/p-IGF-1R/IGF-1R at the protein and/or mRNA levels

Bio informatics analysis of 982 lung cancer patients revealed that higher expression of TNF- alpha was associated with low risk of cancer progression while overexpression of IGF-1 was correlated with high risk. Collectively, these results reveal that the cytokines in the tumor microenvironment differentially modulate radiation therapy through a variety of signaling mechanisms.

These findings reveal that IGFBP3 is effective in lung cancer cells with high IGF1 signaling activity and imply that relevant biomarkers are essential in selecting lung cancer patients for IGF1-targeted therapy

The findings indicated that miR-135a promotes cell apoptosis and inhibits cell proliferation, migration, invasion and tumor angiogenesis by targeting IGF-1 gene through the IGF-1/PI3K/Akt signaling pathway in non-small cell lung cancer.

This study explores the prognostic effect of MET, MET gene copy number, polysomy of chromosome 7, IGF1R gene copy number and IGF-1 expression in tumor epithelial cells of primary non-small-cell lung cancer in 326 patients.

This article reviews the tumor-specific molecular signatures of IGF-1-mediated epithelial-mesenchymal transition in breast, lung, and gastric cancers. [review]

Study found that IL-6, GP130, IGF-1 and IGF-1R were highly expressed in non-small cell lung cancer (NSCLC) and there was the correlation between GP130, IGF-1, and IGF-1R. Co-stimulation of IL-6 and IGF-1 resulted in significantly enhanced cell proliferation, invasion, and apoptosis of NSCLC cells. This experiment revealed that IL-6 and IGF-1 can synergistically promote the progression of NSCLC.

we aimed to evaluate serum levels of IGF-1, IGF-2 and IGF-binding protein 3 (IGF-BP3) before and after standard treatment in patients with advanced non-small cell lung cancer (NSCLC) and their prognostic and predictive correlations.